Nanotechnology in the treatment of cancer
Abstract
Background: Chemotherapy can induce severe side ef ects in patients due to nonselective activity towards healthy cells during the treatment of cancer. h is can lead to an alteration of the dosage regimen and in some cases to premature cancelation of chemotherapy, which reduces its therapeutic ef ect and prolongs the treatment period. Adverse side ef ects can also inl uence the patient’s quality of life during and at er the treatment. Inclusion of anti-tumour drugs in nanocarrier systems can reduce the adverse side ef ects by passive and/or active targeting of tumour cells. Conclusions: Nanocarrier systems achieve passive targeting of tumours through enhanced permeability and retention ef ect (EPR ef ect), which is mainly the result of leakiness of tumour vasculature. Furthermore, active targeting of tumour cells can be achieved through the conjugation of targeting ligands to the surface of nanoparticles, which selectively bind antigens or receptors overexpressed on the surface of tumour cells. In this way, the interaction between healthy tissue and anti-tumour drugs is reduced. Consequently, anti-tumour drugs formulated in nanocarriers have less side-ef ects and are safer in comparison with a free drug, thus enabling higher doses and better ei cay of anti-tumour therapy. To date, European Medicines Agency (EMEA) and Food and Drug Administration (FDA) have approved nine nanocarrier-based medicines for the treatment of cancer. h e safety of nanopar- ticles is yet to be fully explored. However, their toxicity is known to be enhanced with reactive oxygen species, which are associated with inl ammation.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.